Salient Surgical Technologies, Inc. Files Registration Statement for Proposed Initial Public Offering
DOVER, N.H.--(BUSINESS WIRE)--Salient Surgical Technologies, Inc. announced today that it has filed a registration statement with the Securities and Exchange Commission relating to the proposed initial public offering of its common stock. All shares of the common stock to be sold in the offering will be offered by Salient Surgical Technologies.
Bear, Stearns & Co. Inc. and Piper Jaffray & Co. are acting as joint book-running managers and Wachovia Capital Markets, LLC is acting as co-manager for the proposed offering. The offering will be made only by means of a prospectus. Once available, a preliminary prospectus may be obtained from Bear, Stearns & Co. Inc. at 383 Madison Avenue, New York, NY toll-free at (866) 803-9204, Piper Jaffray & Co. at Piper Jaffray & Co., c/o Prospectus Department, 800 Nicollet Mall, Suite 800, Minneapolis, MN 55402 or Wachovia Securities at 375 Park Avenue, New York, NY 10152, (800) 326-5897.
A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Salient Surgical Technologies, Inc.
Salient Surgical Technologies is a medical technology company that develops and markets surgical products based on its proprietary Transcollation™ technology for the sealing of blood vessels and other collagen-based structures. Transcollation technology integrates saline and radiofrequency energy via saline-induced liquid electrodes that deliver thermal energy to selected tissues and bone. Current applications for the Company's Transcollation technology include reducing blood loss during and after orthopedic hip and knee reconstructions, multi-level spinal fusions and surgical oncology. To date, Transcollation technology has been used in over 165,000 surgical procedures.
For more information on Salient Surgical Technologies, visit the Company’s website at www.salientsurgical.com.